Bacterial evolution of antibiotic hypersensitivity.
Lázár V, Pal Singh G, Spohn R, Nagy I, Horváth B, Hrtyan M, Busa-Fekete R, Bogos B, Méhi O, Csörgő B, Pósfai G, Fekete G, Szappanos B, Kégl B, Papp B, Pál C. · 2013
Read Bacterial evolution of antibiotic hypersensitivity. by Lázár V, Pal Singh G, Spohn R, Nagy I, Horváth B, Hrtyan M, Busa-Fekete R, Bogos B, Méhi O, Csörgő B, Pósfai G, Fekete G, Szappanos B, Kégl B, Papp B, Pál C. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3817406.txt.
Introduction
Viktória Lázár and a team of co-authors report an evolution study in Molecular Systems Biology in 2013. They grow Escherichia coli bacteria under drug pressure in the lab. Their question is what happens to a strain's response to other drugs once it resists one drug. Gaining strength against one drug can, at times, bring weakness against others.
Such weakness, called collateral sensitivity, turned up often in their large tests. Strains that adapted to aminoglycoside drugs grew poorly when faced with several other drug types. Gene reads showed why. Changes that cut the cell's inner membrane charge also weakened its drug pumps, so other drugs got in more easily. The work maps a trade-off that drug plans might one day use against resistant germs.
Catalog record
| CREATOR | Lázár V, Pal Singh G, Spohn R, Nagy I, Horváth B, Hrtyan M, Busa-Fekete R, Bogos B, Méhi O, Csörgő B, Pósfai G, Fekete G, Szappanos B, Kégl B, Papp B, Pál C. |
|---|---|
| YEAR | 2013 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Bacterial evolution of antibiotic hypersensitivity By Viktória Lázár, Gajinder Pal Singh, Réka Spohn, István Nagy, Balázs Horváth, Mónika Hrtyan, Róbert Busa-Fekete, Balázs Bogos, Orsolya Méhi, Bálint Csörgő, György Pósfai, Gergely Fekete Published in: Molecular Systems Biology DOI: 10.1038/msb.2013.57 ABSTRACT Abstract The evolution of resistance to a single antibiotic is frequently accompanied by increased resistance to multiple other antimicrobial agents. In sharp contrast, very little is known about the frequency and mechanisms underlying collateral sensitivity. In this case, genetic adaptation under antibiotic stress yields enhanced sensitivity to other antibiotics. Using large-scale laboratory evolutionary experiments with Escherichia coli, we demonstrate that collateral sensitivity occurs frequently during the evolution of antibiotic resistance. Specifically, populations adapted to aminoglycosides have an especially low fitness in the presence of several other antibiotics. Whole-genome sequencing of laboratory-evolved strains revealed multiple mechanisms underlying aminoglycoside resistance, including a reduction in the proton-motive force (PMF) across the inner membrane. We propose that as a side effect, these mutations diminish the activity of PMF-dependent major efflux pumps (including the AcrAB transporter), leading to hypersensitivity to several other antibiotics. More generally, our work offers an insight into the mechanisms that drive the evolution of negative trade-offs under antibiotic selection. Keywords: antibiotic resistance, collateral sensitivity network, evolutionary experiment, trade off INTRODUCTION Evolutionary adaptation to an environment may be accompanied by a decline or an increase in fitness in other environments. Although such trade-offs are frequently observed in nature, the governing rules and the corresponding molecular mechanisms are generally unclear. The evolution of antibiotic resistance offers an ideal model system to systematically investigate this issue. Enhanced level of resistance can be achieved by mutations in the genome or by acquisition of resistance-conferring genes through horizontal gene transfer. The relative contribution of these mechanisms depends both on the antibiotic employed and on the bacterial species considered (Alekshun and Levy, 2007). It has been suggested that the progressive accumulation of mutations can simultaneously change an organism’s sensitivity to many different antimicrobial agents and can serve as the first step in the evolution of clinically significant resistance by more specific and effective mechanisms (Baquero, 2001; Goldstein, 2007; Gullberg et al, 2011). A recent review argued that the evolution of multidrug resistance and hypersensitivity are among the central issues of the field (Palmer and Kishony, 2013). Better understanding of these phenomena is important as they could potentially inform future therapeutic strategies to mitigate resistance evolution. For example, the choice of optimal antibiotic combinations depends on both the presence of physiological drug interactions and the frequency of mutations with pleiotropic fitness effects (Chait et al, 2007; Palmer and Kishony, 2013; Pena-Miller et al, 2013). Specifically, it remains unclear how frequently genetic adaptation to a single antibiotic increases the sensitivity to others and what the underlying molecular mechanisms of hypersensitivity are. No large-scale, systematic laboratory evolution study has been devoted to investigate this problem under controlled environmental settings. To our best knowledge, the only prior work with similar aims was published 60 years ago and was limited to phenomenological descriptions (Szybalski and Bryson, 1952). Here, for the first time, we apply an integrated approach to decipher collateral-sensitivity interactions between antibiotics. We initiated the laboratory evolution of E. coli populations in the presence of one of the several different antimicrobial agents. These antibiotics are well characterized, widely employed in the clinic, and have diverse modes of actions (Table I). Our list also includes antibiotics that are typically used against Gram-positive bacteria. Consistent with previous studies (Curtiss et al, 1965; Vuorio and Vaara, 1992; Elkins and Nikaido, 2002), we found that these antibiotics inhibited the growth of wild-type E. coli at high concentrations and that resistance readily evolved against these compounds (see below). Next, we charted the network of collateral-sensitivity interactions by measuring the susceptibility of each evolved line against all the other antibiotics. Our analysis revealed a strikingly dense network of collateral-sensitivity interactions. Many of these interactions involved aminoglycosides. Finally, laboratory-evolved lines were subjected to whole-genome sequence analysis and biochemical assays to decipher the underlying molecular mechanisms of these interactions. [Table: Employed antibiotics and their modes of actions] RESULTS Parallel evolution of antibiotic susceptibility patterns in the laboratory We followed established protocols with minor modifications to evolve bacterial populations under controlled laboratory conditions (Hegreness et al, 2008). Starting from a single ancestral clone, populations were propagated in batch culture (minimal glucose medium containing a single antibiotic), whereby 1% of each culture was diluted into fresh medium on a daily basis. Microbes frequently encounter low or varying antibiotic concentrations (Baquero, 2001). For example, the limited accessibility of antibiotics to certain tissues or incomplete treatment can lead to the formation of concentration gradients within the body (Kohanski et al, 2010a). Similarly, antibiotic-polluted natural environments generally form such gradients radiating from the source. To mimic these natural conditions, we employed two selection regimes. In the first set of experiments, a fixed sublethal antibiotic concentration (i.e., sufficient to reduce the growth of the starting population by 50%) was employed. Using this set-up, we propagated 10 independent populations in the presence of each antibiotic for ∼140 generations, resulting in 240 parallel-evolved lines. As selection pressure and resistance-conferring mutations can differ substantially between low and high antibiotic concentrations, we also employed a complementary laboratory evolutionary protocol. For an overlapping set of 12 selected antibiotics (Table I), populations were allowed to evolve to successively higher antibiotic concentrations (96 replicate populations per antibiotic). Starting with subinhibitory antibiotic concentrations, the antibiotic concentration was increased every 4 days over a period of 240–384 generations. Despite the short evolutionary timescale, many of the evolved populations reached very high resistance levels (20- to 328-fold increases in the minimum inhibitory concentrations (MICs); Supplementary Table S1). For each antibiotic, we selected 10 independently evolved resistant populations for further analysis (Materials and methods). In addition, to control for potential adaptive changes that are not specific to the employed antibiotics, we also established 10 parallel populations that were grown in an environment devoid of antibiotics, referred to as adapted control lines. Next, we measured the corresponding changes in the sensitivities of all laboratory-evolved populations to other antibiotics. Fitness was measured by monitoring the optical density of liquid cultures of all evolved and control lines in the presence and absence of sublethal concentrations of antibiotics. Our protocol was highly sensitive and could efficiently detect both weak negative and positive trade-offs, which may be overlooked in other assays (Materials and methods; Supplementary Text S1). Furthermore, by measuring fitness in antibiotic-free medium, we could distinguish between general growth defects and genuine collateral-sensitivity interactions. Specifically, we employed a rigorous statistical procedure to identify those collateral-sensitivity interactions that are not expected based on the generally weak growth defect observed in the absence of antibiotics (see Supplementary Text S2 and Supplementary Figure S3). The reliability of the method was confirmed by comparing its results with sensitivity estimates based on the colony size (Supplementary Text S2; Supplementary Figure S1). We noticed that parallel-evolving populations exposed to the same antibiotic displayed very similar antibiotic susceptibility patterns (Supplementary Figure S2). Thus, we developed a data analysis pipeline to infer evolutionary interactions at the level of antibiotic pairs based on the growth patterns of the antibiotic-adapted and control populations. The analysis ultimately led to a map of